Accretion Pharmaceuticals IPO subscription started on Wednesday, May 14, 2025, and will close on May 16, 2025, as per the schedule. The price band is set at ₹96 to ₹101 per share with a face value of ₹10.
Accretion Pharmaceuticals IPO Subscription Status
Accretion Pharmaceuticals IPO subscribed over 7.67x on its last day till 05.00 PM on 16th May 2025.
- Accretion Pharmaceuticals IPO subscription QIB investors portion is 12.14x times, while NII subscribed 4.28x times, and RII investors subscribed 10.54x times.
- The company has received bids for 1,98,42,000 shares against 25,87,200 shares on offer on the last day.
- Accretion Pharmaceuticals IPO subscribed over 7.67 times on day 3.
- Accretion Pharmaceuticals IPO subscribed over 2.35 times on day 2.
- Accretion Pharmaceuticals IPO subscribed over 1.11 times on day 1.
About Accretion Pharmaceuticals IPO
Accretion Pharmaceuticals Limited, established in 2012, is one of the leading pharmaceutical companies involved in the manufacturing and marketing of Tablets, Capsules, and other healthcare products. Other than manufacturing its products for sale, the company also manufactures various pharmaceutical products for other brands through license agreements or contract manufacturing. The company has achieved various certifications, showcasing its commitment to the quality and environmental standards. The manufacturing facility is situated in Ahmedabad, Sanand, Gujarat.
Accretion Pharmaceuticals IPO Company Financial Report
The company reported revenue of ₹33.94 crores in 2024 against ₹29.53 crores in 2023. The company reported a profit of ₹3.88 crores in 2024 against a profit of ₹0.10 crores in 2023.
Accretion Pharmaceuticals IPO GMP:
Accretion Pharmaceuticals’ IPO GMP was ₹5 as of Friday, 16th May. That indicates the IPO is trading at ₹106 with a ₹5 premium in the grey market against the issue price of ₹101.
